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Abstract
Background: In our recent study, tissue proteomic analysis of oral pre-malignant lesions (OPLs) and normal oral mucosa led
to the identification of a panel of biomarkers, including prothymosin alpha (PTMA), to distinguish OPLs from histologically
normal oral tissues. This study aimed to determine the clinical significance of PTMA overexpression in oral squamous cell
hyperplasia, dysplasia and head and neck squamous cell carcinoma (HNSCC).
Methodology: Immunohistochemistry of PTMA protein was performed in HNSCCs (n=100), squamous cell hyperplasia
(n=116), dysplasia (n=50) and histologically normal oral tissues (n=100). Statistical analysis was carried out to determine
the association of PTMA overexpression with clinicopathological parameters and disease prognosis over 7 years for HNSCC
patients.
Results: Our immunohistochemical analysis demonstrated significant overexpression of nuclear PTMA in squamous cell
hyperplasia (63.8%), dysplasia (50%) and HNSCC (61%) in comparison with oral normal mucosa (ptrend,0.001). Chi-square
analysis showed significant association of nuclear PTMA with advanced tumor stages (III+IV). Kaplan Meier survival analysis
indicated reduced disease free survival (DFS) in HNSCC patients (p,0.001; median survival 11 months). Notably, Cox-
multivariate analysis revealed nuclear PTMA as an independent predictor of poor prognosis of HNSCC patients (p,0.001,
Hazard’s ratio, HR=5.2, 95% CI=2.3–11.8) in comparison with the histological grade, T-stage, nodal status and tumor stage.
Conclusions: Nuclear PTMA may serve as prognostic marker in HNSCC to determine the subset of patients that are likely to
show recurrence of the disease.
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Introduction
Human prothymosin alpha (PTMA) is a 12.5 kDa, acid-rich,
non-histone nuclear protein, comprising of 110 amino acids [1].
PTMA is known to play an important role in cell cycle regulation,
proliferation, transcription, chromatin remodeling, oxidative
stress-response and apoptosis [2–8]. Overexpression of PTMA
has been reported in several malignancies such as breast cancer
[5], hepatocarcinoma [9], lung cancer [10], neuroblastoma [11],
bladder cancer [12], gastric [13] and upper urinary tract
transitional cell carcinoma [14]. In addition, PTMA also served
as prognostic marker for cancers of the breast, gastric, prostate and
bladder [5,13,15,16]. Recently, we identified PTMA among the
panel of biomarkers which may find their utility in distinguishing
OPLs and HNSCCs from non-malignant tissues, using isobaric
tags for relative and absolute quantitation (iTRAQ) labeling and
multidimensional liquid chromatography/tandem mass spectrom-
etry (LC-MS/MS) [17].
HNSCC is among the ten most prevalent cancers in the world,
with a higher proportion occurring in developing countries.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19213Tobacco, betel quid and alcohol consumption as well as human
papilloma virus (HPV) are the major risk factors associated with
development of head and neck cancer [18–24]. Oral squamous
cell carcinoma (OSCC), one of the major subtypes of HNSCC, is
often preceded by clinically well-defined lesions, such as
leukoplakia, which is causally linked with chronic exposure of
the oral mucosa to carcinogens/growth promoters in tobacco
and/or betel quid. On an average about 1–2% of these oral lesions
transform into cancer annually [25–27]. Moreover, more than
50% of all HNSCC patients have advanced disease at the time of
diagnosis [28]. Although, there have been advancements in
treatment modalities that improve the quality of life and have
palliative value, the survival rates for HNSCC patients have not
improved markedly (about 50%), often owing to loco-regional
recurrence or second primary tumors observed commonly in the
survivors [27–30]. At present, the most important prognostic
factors for HNSCC are histological tumor grade, stage, depth of
tumor invasion and involvement of regional lymph nodes at the
time of diagnosis. However, none of these factors can predict
prognosis of HNSCC effectively, thus emphasizing the importance
of identifying novel biomarkers for early detection, risk assessment
and accurate prediction of recurrence for this malignancy.
In this study, we aimed to determine the clinical significance of
PTMA overexpression in head and neck tumorigenesis. We
analyzed the expression of PTMA in a large cohort of clinical
samples including normal oral mucosa, squamous cell hyperplasia,
dysplasia and HNSCC by immunohistochemistry. Further, we
investigated correlations of nuclear PTMA expression with
clinicopathological parameters of squamous cell hyperplasia,
dysplasia and HNSCC to determine its utility as a biomarker.
Results
Correlation of nuclear PTMA in squamous cell
hyperplasia, dysplasia and HNSCC with
clinicopathological characteristics
To determine the clinical significance of PTMA protein in
head-and-neck tumorigenesis, its expression was analyzed in
normal oral mucosa, squamous cell hyperplasia, dysplasia and
HNSCC using immunohistochemistry. Figure 1A shows the total
score distribution of nuclear PTMA in normal oral mucosa,
squamous cell hyperplasia, dysplasia and HNSCC. Of the 100
histologically normal tissues analyzed, 88 tissues (88%) showed no
detectable PTMA immunostaining in nuclei of epithelial cells in
normal tissues (Table 1, Figure 1B (i)). PTMA expression was
observed in 5 of 43 (11.6%) paired normal tissues and 7 of 57
(12.3%) unpaired normal tissues only. Chi square trend analysis
also showed significant increase in nuclear expression of PTMA in
tissues obtained from different stages of head-and-neck tumori-
genesis (squamous cell hyperplasia, dysplasia and HNSCC,
ptrend,0.001). Among squamous cell hyperplasia (n=116), 74
cases (63.8%) showed significant increase in nuclear PTMA
immunoreactivity (p,0.001, OR=12.9, 95% CI=6.3–26.3) in
comparison with normal oral tissues (Table 2 and Figure 1B (iii)).
Increased nuclear expression of PTMA was also observed in 50%
dysplasia (25 of 50 cases, p,0.001, OR=7.3, 95% CI=3.2–16.6)
as compared to normal oral tissues (Table 3 and Figure 1B (v)).
Tables 1, 2 and 3 summarize correlations of nuclear PTMA with
clinicopathological parameters of normal oral mucosa, squamous
cell hyperplasia and dysplasia respectively. Interestingly, nuclear
PTMA showed significant association with tobacco consumption
habits of patients with squamous cell hyperplasia (p,0.001).
Among HNSCC, 61% cases showed nuclear localization of
PTMA in tumor cells as compared to normal oral tissues
(p,0.001, OR=11.5, 95% CI=5.7–23.7; Table 4 and
Figure 1B (vii)). The clinicopathological parameters of HNSCC
and their correlations with nuclear PTMA expression are shown in
Table 4. Interestingly, nuclear PTMA showed significant associ-
ation with advanced tumor stage (p=0.03). Notably, none of the
HNSCC tissues showed cytoplasmic PTMA immunostaining. The
positive control (bladder cancer) showed intense nuclear PTMA
expression (Figure 1B (viii)) while no immunostaining was
observed in tissue sections used as negative controls where the
primary antibody was replaced by isotype specific IgG (Figure 1B
(ix)).
The ability of nuclear PTMA to distinguish squamous cell
hyperplasia, dysplasia and HNSCC from normal oral mucosa was
determined by evaluating sensitivity, specificity, positive and
negative predictive values and area-under-the-curve (AUC) using
Receiver Operating Characteristic (ROC) curve analysis. The
values for sensitivity, specificity and AUC for squamous cell
hyperplasia, dysplasia and HNSCC are given in Table 5. The
positive predictive values (PPV) were 86.0, 67.6 and 83.6 for
nuclear expression of PTMA respectively in these three groups
(Table 5).
PTMA overexpression as an independent prognostic
marker for HNSCC
The estimated predictive power of PTMA expression with poor
prognosis was assessed by Kaplan-Meier survival analysis.
HNSCC patients harboring nuclear PTMA showed significantly
reduced disease-free survival (p,0.001; median survival 11
months) as compared to the patients showing no nuclear PTMA
immunostaining (Figure 2d). Cox-multivariate regression analysis
was carried out to determine the prognostic potential of nuclear
PTMA in HNSCC as compared to other clincopathological
parameters including age, gender, histological grade, T-stage,
nodal status and tumor stage. Interestingly, nuclear PTMA
emerged as an independent and most significant predictor of
poor prognosis in HNSCC patients in multivariate analysis
(p,0.001, HR=5.2, 95% CI=2.3–11.8).
Based on our data, the additional prognostic value that nuclear
PTMA expression provided for predicting (PPV) or excluding
(NPV) cancer recurrence in HNSCC patients was measured by the
ratios: PPVrelapse/HNSCC (83 months | PTMA)/PPVrelapse/HNSCC
(83 months)=78.4/61.0; NPVrelapse/HNSCC (83 months |
PTMA)/NPVrelapse/HNSCC (83 months)=73.1/39.0 (Figure 2e &
2f). Hence, these findings clearly demonstrate the potential of
nuclear PTMA as a marker for predicting recurrence in HNSCC.
Verification of PTMA overexpression by RT-PCR and
Immunoblotting
The overexpression of PTMA in squamous cell hyperplasia,
dysplasia and HNSCC in comparison to normal oral mucosa was
verified by RT-PCR and immunoblotting in the same tissue
samples as used for immunohistochemical analysis. Our RT-PCR
analysis demonstrated increased levels of PTMA transcripts in
squamous cell hyperplasia (H1, H2), dysplasia (D1, D2) and
HNSCC (T1, T2, T3) in comparison with normal tissues (N1, N2)
(Figure 3a). Immunoblot analysis using specific antibody for
PTMA clearly showed a single intense band of 12.5 kDa in whole
cell lysates obtained from squamous cell hyperplasia (H1, H2),
dysplasia (D1, D2) and HNSCCs (T1, T2) while no band could be
detected in normal oral mucosa (N1, N2) (Figure 3b). Together,
these findings confirmed overexpression of PTMA in squamous
cell hyperplasia, dysplasia and HNSCC in comparison to normal
oral tissues.
PTMA Overexpression Correlates with Poor Prognosis
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Chronic inflammation in oral mucosa culminates in develop-
ment of OPLs, some of which progress to frank malignancy. In this
multistep model of head and neck tumorigenesis, oral lesions such
as leukoplakia with histopathological evidence of dysplasia, also
considered as pre-malignant or potentially malignant lesions, are
at high risk of progression to cancer - often but not always
correlating with the severity of epithelial dysplasia [31]. However,
oral lesions with squamous cell hyperplasia have been largely
Figure 1. (a) Box-Plot analysis: Box plots showing distribution of total scores based on immunohistochemistry of PTMA protein in paraffin-
embedded sections of oral normal tissues, squamous cell hyperplasia, dysplasia and HNSCC. The vertical axis shows total immunostaining score,
obtained as described in the Methods section. Figure shows total score distribution of nuclear PTMA expression in squamous cell hyperplasia (score
range 0–7), dysplasia (score range 0–7) and HNSCC (score range 0–7). (b) Immunohistochemical analysis of PTMA in head and neck tissues:
Paraffin-embedded sections of histologically oral normal mucosa, squamous cell hyperplasia, dysplasia and HNSCC were stained using anti-PTMA
polyclonal antibody as described in the Methods section. (i) normal oral mucosa showing no PTMA immunostaining; (ii) squamous cell hyperplasia
showing no immunostaining for PTMA; (iii) squamous cell hyperplasia showing nuclear PTMA immunostaining in epithelial cells; (iv) dysplasia
showing no nuclear PTMA immunostaining; (v) dysplasia depicting nuclear PTMA immunostaining in epithelial cells; (vi) HNSCC section showing no
nuclear PTMA staining; (vii) HNSCC section illustrating nuclear PTMA staining in tumor cells; (viii) bladder cancer tissue section showing nuclear PTMA
immunostaining; (ix) HNSCC section used as a negative control, showing no PTMA immunostaining in tumor cells; (i–ix original magnification6200).
doi:10.1371/journal.pone.0019213.g001
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we demonstrated that alterations in protein expression may occur
in early stages of head and neck carcinogenesis i.e. squamous cell
hyperplasia, which might account for the increased proliferation.
Another major clinical challenge is to evaluate the prognosis of
HNSCC effectively, thereby emphasizing the urgent need for
biomarkers that can predict the risk of recurrence in HNSCC. The
salient findings of our study are: (i) significant increase in nuclear
PTMA expression in squamous cell hyperplasia and dysplasia in
comparison with normal oral tissues; (ii) the increased potential of
nuclear PTMA to differentiate squamous cell hyperplasia,
dysplasia and HNSCC from normal oral mucosa with high
sensitivity and specificity; (iii) potential of nuclear PTMA in
predicting recurrence in HNSCC. To the best of our knowledge,
this investigation demonstrates the first clinical evidence of
increased nuclear PTMA expression in pre-malignant lesions
and HNSCC on large scale. Further, current study also verified
our previous report of increased expression of PTMA protein in
OPLs identified using iTRAQ labeling and tissue proteomic
analysis, although in limited number of cases [32].
The significantly increased expression of nuclear PTMA in early
lesions with squamous cell hyperplasia suggests its potential to
Table 1. Analysis of PTMA protein expression in Normal oral mucosa and correlation with clinicopathological parameters.
Clinicopathological Features Total Cases Nuclear Positive N (%) Nuclear Negative N (%) p-value OR (95% CI)
Normal oral mucosa 100 12 (12) 88 (88)
Paired 43 5 (11.6) 38 (88.4) ------ ------
Unpaired 57 7 (12.3) 50 (87.7)
Age (Median, 47 yrs) (16–71 yrs)
,47 67 9 (13.4) 58 (86.6) 0.53 ------
$47 33 3 (9.1) 30 (90.9)
Gender
Male 64 8 (12.5) 56 (87.5) 0.89 ------
Female 36 4 (11.1) 32 (88.9)
Site
Tongue 27 4 (14.8) 23 (85.2)
Buccal Mucosa 13 1 (7.7) 12 (92.3) 0.95 ------
Others (Alveolus, RMT, FOM) 60 7 (11.7) 53 (88.3)
*Habits
Tobacco non- consumers 34 1 (2.9) 33 (97.1) 0.17 ------
Tobacco consumers 35 4 (11.4) 31 (88.6)
*Tobacco consumption habits were available for 69 subjects. RMT, retromolar trigone; FOM, floor of mouth.
doi:10.1371/journal.pone.0019213.t001
Table 2. Analysis of PTMA protein expression in squamous cell hyperplasia and correlation with clinicopathological parameters.
Clinicopathological Features Total Cases Nuclear Positive N (%) Nuclear Negative N (%) p-value OR (95% CI)
Squamous Cell Hyperplasia 116 74 (63.8) 42 (36.2) ,0.001* 12.9 (6.3–26.3)
Age (Median, 38 yrs) (16–69 yrs)
,38 99 68 (68.7) 31 (31.3) 0.008 0.25 (0.08–0.73)
$38 17 6 (35.3) 11 (64.7)
Gender
Male 87 58 (66.7) 29 (33.3) 0.265
Female 29 16 (55.2) 13 (44.8)
Site
Tongue 4 1 (25.0) 3 (75.0)
Buccal Mucosa 83 56 (67.5) 27 (32.5) 0.019
Others (Alveolus, RMT, FOM) 29 17 (58.6) 12 (41.4)
**Habits
Tobacco non- consumers 12 1 (8.3) 11 (91.7) ,0.001 25.9 (3.2–209.3)
Tobacco consumers 104 73 (70.2) 31 (29.8)
*Normal vs. squamous cell hyperplasia;
**Tobacco consumption habits include tobacco chewing (betel quid, areca nut or pan masala) and/or smoking of bidi or cigarettes.
doi:10.1371/journal.pone.0019213.t002
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well supported by the role of nuclear PTMA in regulation of cell
cycle and proliferation [33]. Further, increased nuclear PTMA
expression has also been reported in response to inflammation.
Notably, thymosin alpha1 derived from its precursor PTMA has
been reported to be an endogenous regulator of immune
homeostasis that controls inflammation, immunity, and tolerance
in a variety of clinical settings [34]. Importantly, chronic
inflammation has been widely linked to the development of
HNSCC [35] and our present findings of nuclear PTMA
overexpression in squamous cell hyperplasia, dysplasia and frank
tumors tempts us to speculate role of PTMA in linking
inflammation and cancer development. We also recognize the
possible link between nuclear PTMA expression and risk of cancer
development needs confirmation in a long term follow-up study of
patients with squamous cell hyperplasia; such longitudinal studies
are challenging but these patients are being followed up for regular
monitoring of disease progression.
In support of our findings, Suzuki et al., reported increased
nuclear PTMA expression with progression from normal
epithelium, through prostatic intraepithelial neoplasia to carci-
nomas, suggesting its involvement in differentiation and progres-
sion of prostate cancer [15]. Several other studies have also
suggested a similar role for PTMA in cellular proliferation as an
oncoprotein [5–7,33,36–38]. PTMA is not only related to
proliferation, but is directly involved in the process, probably as
an early component in the proliferation events triggered by the
myc genes [8,39]. It also affects the activity of specific
transcription factors, including the estrogen receptor (ER), p53,
p21 and signal transducers and activators of transcription 3
[36,40,41]. Notably, PTMA expression is positively regulated by
estrogen RNA binding protein, HuR, c-myc and E2F, while p53
acts as a negative transcriptional regulator [40,42–44]. Further-
more, PTMA interacts with histones and affects chromatin
remodeling processes [36,45–47]. In addition, the role of PTMA
in adhesion, migration and proliferation has been reported in
human ovarian cancer [48].
Most importantly, in our study nuclear PTMA expression
emerged as an independent poor prognosticator in multivariate
analysis, in comparison with the known clinical and pathological
factors for HNSCC including histological grade [well differen-
tiated (WD), moderately differentiated (MD) and poorly
differentiated (PD)], T-stage, lymph node positivity and tumor
stage. Further, analysis of the predictive potential of PTMA
revealed its utility as a marker to identify aggressive HNSCC,
supporting the association observed by Kaplan–Meier analysis
and logistic regression analysis. Taken together, these findings
demonstrated the potential of nuclear PTMA as a potential
marker for predicting poor prognosis of HNSCC. However,
biological role of PTMA in HNSCC progression and recurrence
is not clearly understood, thus warranting further investigations
in future studies. Altered expression profiling of PTMA has also
been reported in several other malignancies [5,9–12,14].
Overexpression of PTMA has been reported in several
neoplasms and the expression level is associated with prognosis,
metastatic potential and overall survival of the patients. Its
overexpression in breast cancer is associated with metastatic
potential of tumor and with the risk of death [5]. It has been
reported as a potential biomarker in colon cancer [49], a tumor
marker for detection of transitional cell carcinoma of urinary
bladder [16] and prognosticator in upper urinary tract
transitional cell carcinoma [14].
In conclusion, nuclear PTMA was observed in majority of
squamous cell hyperplasia dysplasia and HNSCC. Large-scale
longitudinal studies are warranted for evaluating the potential of
PTMA overexpression to identify patients with oral lesions at high
risk of cancer development. Further, our study demonstrated
significance of nuclear PTMA as poor prognosticator of HNSCC.
Table 3. Analysis of PTMA protein expression in dysplasia and correlation with clinicopathological parameters.
Clinicopathological Features Total Cases Nuclear Positive N (%) Nuclear Negative N (%) p-value OR (95% CI)
Dysplasia 50 25 (50.0) 25 (50.0) ,0.001
* 7.3 (3.2–16.6)
Age (Median, 45 yrs) (20–75 yrs)
,45 22 12 (54.5) 10 (45.5) 0.569 -----
$45 28 13 (46.4) 15 (53.6)
Gender
Male 43 21 (48.8) 22 (51.2) 0.684 -----
Female 7 4 (57.1) 3 (42.9)
Site
Tongue 7 2 (28.6) 5 (71.4)
Buccal Mucosa 33 18 (54.5) 15 (45.5) 0.317 -----
Others (Alveolus, RMT, FOM) 10 5 (50.0) 5(50.0)
Histopathological grade
Mild Dysplasia 39 20 (51.3) 19 (48.7) 0.73 -----
Moderate Dysplasia 9 4 (44.4) 5 (55.6)
Severe Dysplasia 2 1 (50.0) 1 (50.0)
**Habits
Tobacco non- consumers 0 0 0 ----- -----
Tobacco consumers 50 25 (50.0) 25 (50.0)
*Normal vs. dysplasia; Squamous cell hyperplasia vs. dysplasia, p=0.097;
**Tobacco consumption habits include tobacco chewing (betel quid, areca nut or pan masala) and/or smoking of bidi or cigarettes.
doi:10.1371/journal.pone.0019213.t003
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Patients and clinicopathological data collection, tissue
specimens
The Institutional Human Ethics Committee of the All India
Institute of Medical Sciences (AIIMS), New Delhi, India,
approved this study prior to its commencement. A written
informed consent approved by ethical committee was obtained
from all participants involved in the study. Tissue specimens were
obtained by diagnostic or therapeutic procedures from patients
showing features of squamous cell hyperplasia (n=116), or
dysplasia (n=50) attending the Outpatient Clinic of the
Departments of Surgical Disciplines and Otorhinolaryngology,
AIIMS, and from 100 HNSCC patients undergoing curative
cancer surgery during the period 2002–2007, after obtaining the
patients’ consent. Wherever possible, non-malignant paired tissues
(n=43) were taken from a site distant from the surgically resected
HNSCC. Non-malignant unpaired oral tissues (n=57) were also
collected from the patients attending the Outpatient Department
of Dental Surgery for tooth extraction. Taken together, these 100
non-malignant oral tissues with histological evidence of normal
epithelia constituted the normal group. After excision, tissues were
immediately snap-frozen in liquid nitrogen and stored at 280uCi n
the Research Tissue Bank till further use; one part of the tissue was
Table 4. Analysis of PTMA protein expression in HNSCC and correlation with clinicopathological parameters.
Clinicopathological Features Total Cases Nuclear Positive N (%) Nuclear Negative N (%) p-value OR (95% CI)
HNSCC 100 61 (61.0) 39 (39.0) ,0.001
* 11.5 (5.7–23.7)
Age (Median, 53 yrs) (25–85 yrs)
,53 49 28 (57.1) 21 (42.9) 0.43 -----
$53 51 33 (64.7) 18 (35.3)
Gender
Male 75 45 (60.0) 30 (40.0) 0.72 -----
Female 25 16 (64.0) 9 (36.0)
Site
Tongue 44 26 (59.1) 18 (40.1)
Buccal Mucosa 31 17 (54.8) 14 (45.2) ----- -----
Others (Alveolus, Lip, RMT, FOM) 25 18 (72.0) 7 (28.0)
Histopathological grade 100 74 (63.8) 42 (36.2)
WDSCC 45 25 (55.6) 20 (44.4) 0.55 1.3 (0.6–2.9)
MDSCC 49 32 (65.3) 17 (34.7)
PDSCC 6 4 (66.7) 2 (33.3)
T-Stage
T1+T2 39 21 (53.8) 18 (46.2) 0.24 -----
T3+T4 61 40 (65.6) 21 (34.4)
Nodal Status
N0 33 16 (48.5) 17 (51.5) 0.07 -----
N1–3 67 45 (67.2) 22 (32.8)
Tumor Stage
I+II 20 8 (40.0) 12 (60.0) 0.031 2.9 (1.1–8.1)
III+IV 80 53 (66.3) 27 (33.7)
**Habits
Tobacco non- consumers 22 13 (59.1) 9 (40.9) 0.83 -----
Tobacco consumers 78 48 (61.5) 30 (38.5)
*Normal vs. HNSCC;
**Tobacco consumption habits include tobacco chewing (betel quid, areca nut or pan masala) and/or smoking of bidi or cigarettes.
doi:10.1371/journal.pone.0019213.t004
Table 5. Biomarker analysis of PTMA in squamous cell hyperplasia, dysplasia and HNSCC.
PTMA Sensitivity Specificity PPV NPV AUC
1) Normal vs. Squamous cell hyperplasia 63.8 88.0 86.0 67.7 0.764
2) Normal vs. Dysplasia 50.0 88.0 67.6 77.9 0.708
3) Normal vs. HNSCC 61.0 88.0 83.6 69.3 0.765
doi:10.1371/journal.pone.0019213.t005
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histopathological and immunohistochemical analysis. The histo-
logically confirmed oral normal epithelia, oral lesions with
squamous cell hyperplasia or with dysplasia, and HNSCC as
revealed by H and E staining were used for immunohistochemistry
as described earlier [17]. The patients’ demographic, clinical, and
pathological data were recorded in a pre-designed performa as
described previously [17,50]. The information documented
included clinical TNM staging (tumor, node, metastasis based on
the Union International Center le Cancer TNM classification of
malignant tumors 2002), site of the lesion, histopathological grade
(WD, MD, PD), age, gender, and tobacco consumption habits.
Follow-up Study
Seventy-seven HNSCC patients who underwent treatment from
2002–2007 were investigated and evaluated in the head-and-neck
cancer follow-up clinic at regular time intervals. Survival status of
the HNSCC patients was verified and updated from the records of
the Tumor Registry, Institute Rotary Cancer Hospital, AIIMS, as
of December 2009. HNSCC patients were monitored for a
maximum period of 83 months. As per the hospital protocol
described earlier [50,51], HNSCC patients with T1 and T2 tumors
were treated with surgery alone, whereas the majority of patients
with T3 and T4 diseases were treated by radical surgery followed
by postoperative radical radiotherapy. The patients were revisited
clinically on a regular basis and the time to recurrence was
recorded. If a patient died, the survival time was censored at the
time of death; the medical history, clinical examination, and
radiological evaluation were used to determine whether the death
had resulted from recurrent cancer (relapsing patients) or from any
other causes. Disease-free survivors were defined as patients free
from clinical and radiological evidence of local, regional, or distant
relapse at the time of the last follow-up. Loco-regional relapse/
death was observed in 51 of 77 (66%) patients monitored during
the follow-up. Twenty six patients who did not show recurrence
were alive until the end of follow-up period. Only disease-free
Figure 2. Survival analysis in HNSCC patients: (a) Kaplan–Meier estimation of cumulative proportion of disease-free survival, median time for
disease-free survival (DFS: no recurrence/metastasis) in HNSCC patients showing nuclear immunostaining of PTMA was 11 months as compared to
the patients showing no nuclear PTMA immunostaining (p,0.001); (b) Positive Predictive Values: Positive Predictive Values [PPV(t)] for time to
cancer relapse for 51 HNSCC patients with PTMA(+) (solid line) and for all 77 HNSCC patients with survival data (dashed line); (c) Negative
Predictive Values: Negative Predictive Values [NPV(t)] for time to cancer relapse for 26 patients with PTMA (2) (solid line), and for all 77 patients
(dashed line).
doi:10.1371/journal.pone.0019213.g002
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deaths due to disease progression did not allow a reliable statistical
analysis. Disease-free survival was expressed as the number of
months from the date of surgery to loco-regional relapse/death.
Immunohistochemistry
Paraffin-embedded sections (5 mm) of human normal oral
mucosa (n=100), squamous cell hyperplasia (n=116), dysplasia
(n=50) and HNSCC (n=100) were collected on gelatin-coated
slides. In brief, the sections were deparaffinized in xylene,
hydrated in gradient alcohol, and pre-treated in a microwave
oven for 10 min at 800 W and 5 min at 480 W in Tris - EDTA
buffer (0.01 M, pH=9.0) for antigen retrieval. The sections were
incubated with hydrogen peroxide (0.3% v/v) in methanol for
30 min to quench the endogenous peroxidase activity, followed
by blocking with 1% bovine serum albumin (BSA) to preclude
non-specific binding. Thereafter, the slides were incubated with
goat polyclonal anti-PTMA (N-18) antibody (4 mg/ml, sc-18205,
Santa Cruz Biotechnology, CA) for 16 h at 4uC. The primary
antibody was detected using the streptavidin-biotin complex with
the Dako LSAB plus kit (Dako CYTOMATION, Glostrup,
Denmark) and diaminobenzidine as the chromogen [32]. All
procedures were carried out at room temperature unless
otherwise specified. Slides were washed with Tris-buffered saline
(TBS, 0.1 M, pH=7.4), 3–5 times after each step. Finally, the
sections were counterstained with Mayer’s hematoxylin and
mounted with D.P.X mountant. In the negative control tissue
sections, the primary antibody was replaced by isotype specific
non-immune mouse IgG. Tissue sections from bladder cancer
were used as a positive control for PTMA expression [12]. The
sections were evaluated by light microscopic examination using
Olympus BX51 microscope.
Evaluation of immunohistochemical staining
Each slide was evaluated for PTMA immunostaining using a
semi-quantitative scoring system for both staining intensity and the
percentage of positive epithelial cells as described earlier [50].
Immunopositive staining was evaluated in randomly selected five
areas of the tissue section. For PTMA protein expression, sections
were scored as positive, if epithelial cells showed immunopositivity
in the nucleus when observed independently by four of us (SCT,
AM, JK, SDG), who were blinded to the clinical outcome (the
slides were coded and the scorers did not have prior knowledge of
the local tumor burden, lymphonodular spread, and grading of the
tissue samples). The tissue sections were scored based on the % of
immunostained cells as: 0–10%=0; 10–30%=1; 30–50%=2;
50–70%=3 and 70–100%=4. Sections were also scored semi-
quantitatively on the basis of staining intensity as negative=0;
mild=1; moderate=2; intense=3 [50]. Finally, a total score was
obtained by adding the score of percentage positivity and intensity.
The scoring by all four observers (SCT, AM, JK, SDG) was
discrepant in about 5% cases and a consensus on the final result
was reached by re-evaluation of these slides and discussion.
Statistical Analysis
The immunohistochemical data were subjected to statistical
analysis using the SPSS 13.0 software (Chicago). Sensitivity and
specificity were calculated and quantified using receiver operating
characteristic (ROC) curve analysis. The predictive value (PV)
describes the proportion of correctly classified cases. Based on
sensitivity and specificity values for PTMA, a cut-off $2 was
defined as positive criterion for nuclear PTMA immunopositivity
for statistical analysis. The relationships between PTMA protein
expression and clinicopathological parameters were tested using
Chi-Square and Fischer’s exact test. Two-sided p values were
Figure 3. Verification of PTMA overexpression: (a) RT-PCR analysis of PTMA in normal mucosa, squamous cell hyperplasia, dysplasia and HNSCC
tissues. Panel shows increased levels of PTMA transcripts in squamous cell hyperplasia (H1, H2), dysplasia (D1, D2) and HNSCC (T1, T2, T3) compared
with the normal oral mucosa (N1, N2) that showed basal levels of PTMA transcripts. b-actin was used as a control to normalize the quantity of RNA
used for each RT-PCR reaction is shown in the lower panel. (b) Immunoblot analysis: Immunoblot analysis of PTMA in normal oral mucosa (N1, N2),
squamous cell hyperplasia (H1, H2), dysplasia (D1, D2) and HNSCC (T1, T2). Equal amount of protein lysates were electrophoresed on 12% SDS-PAGE
and transferred to PVDF membrane. The membrane was incubated with respective primary antibodies and secondary antibodies as described in the
Methods section and the signal detected by enhanced chemiluminescence method. Panel shows increased expression of PTMA in squamous cell
hyperplasia (H1, H2), dysplasia (D1, D2) and HNSCC (T1, T2) compared with normal oral mucosa (N1, N2). GAPDH was used as loading control (lower
panel).
doi:10.1371/journal.pone.0019213.g003
PTMA Overexpression Correlates with Poor Prognosis
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19213calculated and p,0.05 was considered to be significant. Similarly,
positive predictive value (PPV) and negative predictive value
(NPV) was calculated for squamous cell hyperplasia, dysplasia and
HNSCC with respect to normal tissues.
The correlation of PTMA staining with patient survival was
evaluated using life tables constructed from survival data with
Kaplan-Meier plots [50]. Multivariate analysis was carried out
using Cox regression model which included PTMA overexpression
and clinicopathological parameters such as age, gender, histolog-
ical grade, T-stage, nodal status and tumor stage. The systematic
and rigorous assessment of Positive and Negative Predictive Values
(PPV and NPV respectively) for prognostic biomarkers was carried
out as described earlier [50]. For the follow-up study of HNSCC,
let T denote the failure time, i.e., the first time recurrence is
diagnosed after surgical removal of the tumor. For these data, the
positive and negative predictive values as functions of time are
defined as follows: PPVtumor(t)=Prob (T#t and Recurrence|
PTMA (nuclear)$2); NPVtumor(t)=Prob (T.t OR No Recur-
rence| PTMA (nuclear),2); 0#t#83, These probabilities are
estimated from the observed accumulated incidences over the
respective time periods [52].
Reverse Transcription-PCR
Representative frozen tissue specimens of histologically con-
firmed oral normal tissues (n=5), squamous cell hyperplasia
(n=5), dysplasia (n=5) and HNSCC (n=5) were used for
extraction of total RNA using the TRI reagent (Sigma, MO) as
previously described [53]. First-strand cDNA was synthesized
using 2 mg RNA with oligo dT as the primer with MMLV reverse
transcriptase. PCR was carried out using PTMA specific primers
forward (59-ATGTCAGACGCAGCCGTAGACACCA-39) and
reverse (59-CTAGTCATCCTCGTCGGTCTTCTGC-39) [11].
Twenty microliters of each PCR product was used for electro-
phoresis on a 1.2% agarose gel and photographed using
ChemiImager system.
Immunoblot analysis of PTMA in oral tissues
Whole-cell lysates were prepared from oral normal mucosa
(n=5), squamous cell hyperplasia (n=5), dysplasia (n=5), and
HNSCC (n=5) tissues by homogenization in lysis buffer
containing 50 mM Tris-Cl (pH=7.5), 150 mM NaCl, 10 mM
MgCl2, 1 mM ethylenediamine tetraacetate (EDTA, pH=8.0),
1% Nonidet P-40, 1 mM phenylmethylene sulfonylfluoride
(PMSF) and 2 ml/ml protease inhibitor cocktail (Sigma) as
previously described [17,32]. Protein concentration was deter-
mined using the Bradford reagent (Sigma) and equal amounts of
proteins (50 mg/lane) were resolved on 12% sodium dodecyl
sulfate (SDS)-polyacrylamide gel. The proteins were then electro-
transferred onto polyvinylidene-difluoride (PVDF) membrane.
After blocking with 5% non-fat powdered milk in Tris-buffered
saline (TBS, 0.1 M, pH=7.4), blots were incubated with
polyclonal anti-PTMA antibody (2 mg/ml, sc-18205, Santa Cruz
Biotechnology, CA) at 4uC overnight. Protein abundance of
GAPDH (mouse monoclonal antibody, Abcam Inc., Cambridge,
MA) served as a control for protein loading in each lane.
Membranes were incubated with their respective HRP-conjugated
secondary antibody, (DAKO Cytomation, Glostrup, Denmark),
diluted at an appropriate dilution in 1% BSA, for 2 h at room
temperature. After each step, blots were washed three times with
Tween (0.1%)-Tris-buffer saline (TTBS). Protein bands were
detected by the enhanced chemiluminescence method (ECL,
Pierce, IL) on XO-MAT film.
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